SHERBOC: A Double-blind, Placebo-controlled, Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Seribantumab (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SHERBOC
- Sponsors Merrimack Pharmaceuticals
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.
- 07 Aug 2017 Status changed from planning to not yet recruiting.
- 10 Jan 2017 New trial record